TransCode Therapeutics In... (RNAZ)
TransCode Therapeutics Statistics
Share Statistics
TransCode Therapeutics has 23.34M shares outstanding. The number of shares has increased by 256.81% in one year.
| Shares Outstanding | 23.34M |
| Shares Change (YoY) | 256.81% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.09% |
| Shares Floating | 20.98M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 743.58K, so 106.8% of the outstanding shares have been sold short.
| Short Interest | 743.58K |
| Short % of Shares Out | 106.8% |
| Short % of Float | 106.93% |
| Short Ratio (days to cover) | 0.5 |
Valuation Ratios
The PE ratio is -0.05 and the forward PE ratio is -2.23. TransCode Therapeutics's PEG ratio is 0.
| PE Ratio | -0.05 |
| Forward PE | -2.23 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.59 |
| P/FCF Ratio | -0.05 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for TransCode Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.27.
| Current Ratio | 1.28 |
| Quick Ratio | 1.28 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.02 |
| Interest Coverage | -383.66 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.32M |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.15, so TransCode Therapeutics's price volatility has been higher than the market average.
| Beta | 1.15 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 0.32 |
| Relative Strength Index (RSI) | 68.79 |
| Average Volume (20 Days) | - |
Income Statement
| Revenue | n/a |
| Gross Profit | -516.75K |
| Operating Income | -19.42M |
| Net Income | -18.55M |
| EBITDA | -17.97M |
| EBIT | -18.49M |
| Earnings Per Share (EPS) | -103.61 |
Balance Sheet
The company has 2.77M in cash and 450.57K in debt, giving a net cash position of 2.32M.
| Cash & Cash Equivalents | 2.77M |
| Total Debt | 450.57K |
| Net Cash | 2.32M |
| Retained Earnings | -46.42M |
| Total Assets | 3.94M |
| Working Capital | 1.33M |
Cash Flow
In the last 12 months, operating cash flow was -18.07M and capital expenditures -35.61K, giving a free cash flow of -18.11M.
| Operating Cash Flow | -18.07M |
| Capital Expenditures | -35.61K |
| Free Cash Flow | -18.11M |
| FCF Per Share | -101.17 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RNAZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for RNAZ.
| Price Target | $20 |
| Price Target Difference | n/a |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Dec 4, 2024. It was a backward split with a ratio of 1:33.
| Last Split Date | Dec 4, 2024 |
| Split Type | backward |
| Split Ratio | 1:33 |
Scores
| Altman Z-Score | -32.12 |
| Piotroski F-Score | 1 |